Tim joined Horizon Pharma in June 2008 as president and chief executive officer and has served as chairman of our board of directors since 2010. Prior to joining Horizon Pharma plc, he served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Tim served as executive vice president, commercial operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, he served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Tim served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth. Tim received his Bachelor of Arts in Business from Muhlenberg College, in Allentown, Pa.. He serves as chairman of the board of Egalet Corporation (NASDAQ: EGLT) and the Illinois Biotechnology Innovation Organization (iBIO) and sits on the board of directors of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC) and the Greater Chicago Arthritis Foundation. He is also a member of the Illinois Innovation Council.

 Experienced in the global development of drug industry.